Nuwellis Overview
Valuation check: NUWE's ROE is 541.02%, above the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow541.02%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Nuwellis (NUWE) currently reports a ROE of 541.02%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Nuwellis's ROE history and peer comparisons.
Nuwellis's ROE of 541.02% is higher than the Healthcare sector average of 11.15%. That is roughly 4750.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Nuwellis's current 541.02% should be judged against Healthcare norms (sector average: 11.15%) and against NUWE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 541.02%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Nuwellis, and consider following NUWE for alerts when major investors trade the stock.
Nuwellis is classified in the Healthcare sector. On ROE, it currently shows 541.02% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NUWE with unrelated industries.
